Evidence map›Paper›PMID 29101326›Full record

ArticleScientific reports2017

Monitoring and manipulating cellular crosstalk during kidney fibrosis inside a 3D in vitro co-culture.

Bramasta Nugraha, Manuel A Mohr, Aaron Ponti, Maximilian Y Emmert, Franziska Weibel, Simon P Hoerstrup, Solange Moll, Ulrich Certa, Marco Prunotto, Periklis Pantazis

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Bramasta NugrahaDepartment of Biosystems Science and Engineering (D-BSSE), Eidgenössische Technische Hochschule (ETH) Zurich, Mattenstrasse 26, 4058, Basel, Switzerland.
Manuel A MohrDepartment of Biosystems Science and Engineering (D-BSSE), Eidgenössische Technische Hochschule (ETH) Zurich, Mattenstrasse 26, 4058, Basel, Switzerland.ORCID 0000-0002-5189-541X
Aaron PontiDepartment of Biosystems Science and Engineering (D-BSSE), Eidgenössische Technische Hochschule (ETH) Zurich, Mattenstrasse 26, 4058, Basel, Switzerland.ORCID 0000-0003-4406-3508
Maximilian Y EmmertInstitute for Regenerative Medicine (IREM), University of Zurich, Wagistrasse 12, 8952, Schlieren, Switzerland.
Franziska WeibelRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, 4070, Basel, Switzerland.
Simon P HoerstrupInstitute for Regenerative Medicine (IREM), University of Zurich, Wagistrasse 12, 8952, Schlieren, Switzerland.
Solange MollDepartment of Pathology, University Hospital of Geneva, Geneva, Switzerland.
Ulrich CertaRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, 4070, Basel, Switzerland.
Marco PrunottoRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, 4070, Basel, Switzerland. marco.prunotto@roche.com.
Periklis PantazisDepartment of Biosystems Science and Engineering (D-BSSE), Eidgenössische Technische Hochschule (ETH) Zurich, Mattenstrasse 26, 4058, Basel, Switzerland. periklis.pantazis@bsse.ethz.ch.ORCID 0000-0002-8367-9332
Roche (Switzerland) · CHBoard of the Swiss Federal Institutes of Technology · CHUniversity of Zurich · CHUniversity Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In pharmacological research the development of promising lead compounds requires a detailed understanding of the dynamics of disease progression. However, for many diseases, such as kidney fibrosis, gaining such understanding requires complex real-time, multi-dimensional analysis of diseased and healthy tissue. To allow for such studies with increased throughput we established a dextran hydrogel-based in vitro 3D co-culture as a disease model for kidney fibrosis aimed at the discovery of compounds modulating the epithelial/mesenchymal crosstalk. This platform mimics a simplified pathological renal microenvironment at the interface between tubular epithelial cells and surrounding quiescent fibroblasts. We combined this 3D technology with epithelial reporter cell lines expressing fluorescent biomarkers in order to visualize pathophysiological cell state changes resulting from toxin-mediated chemical injury. Epithelial cell damage onset was robustly detected by image-based monitoring, and injured epithelial spheroids induced myofibroblast differentiation of co-cultured quiescent human fibroblasts. The presented 3D co-culture system therefore provides a unique model system for screening of novel therapeutic molecules capable to interfere and modulate the dialogue between epithelial and mesenchymal cells.

Indexed as

Coculture TechniquesCell CommunicationCell DifferentiationCell LineEpithelial CellsFibrosisGene ExpressionHumansKidneyKidney DiseasesModels, BiologicalMyofibroblastsTissue Scaffolds

Identifiers

PMID29101326
PMCPMC5670242
OpenAlexW2765670642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.